S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
NASDAQ:STSA

Satsuma Pharmaceuticals Stock Forecast, Price & News

$4.58
-0.09 (-1.93%)
(As of 01/21/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.43
$4.60
50-Day Range
$4.15
$6.01
52-Week Range
$4.05
$7.48
Volume
30,863 shs
Average Volume
41,940 shs
Market Capitalization
$144.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.35
30 days | 90 days | 365 days | Advanced Chart
Receive STSA News and Ratings via Email

Sign-up to receive the latest news and ratings for Satsuma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Satsuma Pharmaceuticals logo

About Satsuma Pharmaceuticals

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Headlines

STSA Oct 2021 2.500 put
September 28, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Regional Banks
Sector
Medical
Current Symbol
NASDAQ:STSA
CUSIP
85931930
Fax
N/A
Employees
19
Year Founded
2016

Sales & Book Value

Annual Sales
N/A
Book Value
$4.13 per share

Profitability

Net Income
$-47.56 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
22,007,000
Market Cap
$144.40 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/09/2021
Today
1/22/2022
Next Earnings (Estimated)
3/24/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.50 out of 5 stars

Medical Sector

131st out of 1,418 stocks

Pharmaceutical Preparations Industry

50th out of 684 stocks

Analyst Opinion: 3.3Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.0 5 -4 -3 -2 -1 -












Satsuma Pharmaceuticals (NASDAQ:STSA) Frequently Asked Questions

Is Satsuma Pharmaceuticals a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Satsuma Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Satsuma Pharmaceuticals stock.
View analyst ratings for Satsuma Pharmaceuticals
or view top-rated stocks.

How has Satsuma Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Satsuma Pharmaceuticals' stock was trading at $23.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, STSA shares have decreased by 80.7% and is now trading at $4.58.
View which stocks have been most impacted by COVID-19
.

When is Satsuma Pharmaceuticals' next earnings date?

Satsuma Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Satsuma Pharmaceuticals
.

How were Satsuma Pharmaceuticals' earnings last quarter?

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) issued its quarterly earnings data on Tuesday, November, 9th. The financial services provider reported ($0.42) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.51) by $0.09.
View Satsuma Pharmaceuticals' earnings history
.

What price target have analysts set for STSA?

4 equities research analysts have issued 1-year target prices for Satsuma Pharmaceuticals' shares. Their forecasts range from $5.00 to $15.00. On average, they expect Satsuma Pharmaceuticals' stock price to reach $10.38 in the next twelve months. This suggests a possible upside of 126.5% from the stock's current price.
View analysts' price targets for Satsuma Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Satsuma Pharmaceuticals' key executives?

Satsuma Pharmaceuticals' management team includes the following people:
  • Mr. John A. Kollins, Pres, CEO & Director (Age 58, Pay $585.79k)
  • Mr. Thomas P. O'Neil, Chief Financial Officer (Age 56, Pay $436.96k)
  • Dr. Detlef F. Albrecht, Chief Medical Officer (Age 60, Pay $501.15k)
  • Mr. Mic Iwashima, VP & Head of Operations (Age 43)
  • Mr. Robert Schultz, VP & Head of CMC (Age 57)
  • Dr. Shannon Strom Ph.D., VP & Head of Regulatory Affairs (Age 45)
  • Mr. Robert M. Janosky, Chief Commercial Officer
  • Mr. Alan C. Mendelson J.D., Sec. (Age 71)

What other stocks do shareholders of Satsuma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Satsuma Pharmaceuticals investors own include Verrica Pharmaceuticals (VRCA), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Dynavax Technologies (DVAX), Homology Medicines (FIXX), Gilead Sciences (GILD), Novan (NOVN), Pfizer (PFE) and Akebia Therapeutics (AKBA).

When did Satsuma Pharmaceuticals IPO?

(STSA) raised $75 million in an IPO on Friday, September 13th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Credit Suisse, SVB Leerink and Evercore served as the underwriters for the IPO.

What is Satsuma Pharmaceuticals' stock symbol?

Satsuma Pharmaceuticals trades on the NASDAQ under the ticker symbol "STSA."

How do I buy shares of Satsuma Pharmaceuticals?

Shares of STSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Satsuma Pharmaceuticals' stock price today?

One share of STSA stock can currently be purchased for approximately $4.58.

How much money does Satsuma Pharmaceuticals make?

Satsuma Pharmaceuticals has a market capitalization of $144.40 million. The financial services provider earns $-47.56 million in net income (profit) each year or ($2.00) on an earnings per share basis.

How many employees does Satsuma Pharmaceuticals have?

Satsuma Pharmaceuticals employs 19 workers across the globe.

When was Satsuma Pharmaceuticals founded?

Satsuma Pharmaceuticals was founded in 2016.

What is Satsuma Pharmaceuticals' official website?

The official website for Satsuma Pharmaceuticals is www.satsumarx.com.

Where are Satsuma Pharmaceuticals' headquarters?

Satsuma Pharmaceuticals is headquartered at 400 OYSTER POINT BOULEVARD SUITE 221, SOUTH SAN FRANCISCO CA, 64080.

How can I contact Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals' mailing address is 400 OYSTER POINT BOULEVARD SUITE 221, SOUTH SAN FRANCISCO CA, 64080. The financial services provider can be reached via phone at 650-410-3200.


This page was last updated on 1/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.